Compare UAMY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UAMY | MURA |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.0M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | UAMY | MURA |
|---|---|---|
| Price | $5.03 | $2.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.69 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 8.3M | 224.8K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,857,819.00 | N/A |
| Revenue This Year | $159.13 | N/A |
| Revenue Next Year | $228.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 177.97 | N/A |
| 52 Week Low | $1.21 | $0.95 |
| 52 Week High | $19.71 | $4.74 |
| Indicator | UAMY | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 40.39 |
| Support Level | $5.16 | $2.06 |
| Resistance Level | $6.95 | $2.10 |
| Average True Range (ATR) | 0.53 | 0.01 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 3.28 | 25.00 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.